Skip to main content
SpringerLink
Log in

Safety Considerations for Intraoperative Use of Cytostatic Agents

  • Chapter
  • First Online:
Peritoneal Tumors and Metastases

  • 484 Accesses

Abstract

Different cytostatic agents are used in the OR in the context of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). These drugs are classified as hazardous and mutagenic substances. Thus, staff and patient safety should always be considered during HIPEC and guaranteed by legal regulations, institutional standard operating procedures, and consisting safety measures. The main object of all safety considerations is the avoidance of contamination.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gonzalez-Moreno S, Gonzalez-Bayon L, Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: methodology and safety considerations. Surg Oncol Clin N Am. 2012;21:543–57.

    Article  Google Scholar 

  2. Konate A, Poupon J, Villa A, Garnier R, Hasni-Pichard H, et al. Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure. J Surg Oncol. 2011;103:6–9.

    Article  Google Scholar 

  3. Kyriazanos I, Kalles V, Stefanopoulos A, Spiliotis J, Mohamed F. Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Surg Oncol. 2016;25:308–14.

    Article  Google Scholar 

  4. Naslund Andreasson S, Anundi H, Thoren SB, Ehrsson H, Mahteme H. Is platinum present in blood and urine from treatment givers during hyperthermic intraperitoneal chemotherapy? J Oncol. 2010;2010:649719.

    Article  Google Scholar 

  5. Neuss MN, Polovich M, McNiff K, Esper P, Gilmore TR, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract. 2013;9:5s–13s.

    Article  Google Scholar 

  6. Schierl R, Novotna J, Piso P, Bohlandt A, Nowak D. Low surface contamination by cis/oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol. 2012;38:88–94.

    Article  CAS  Google Scholar 

  7. Schmid K, Boettcher MI, Pelz JO, Meyer T, Korinth G, et al. Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C. Eur J Surg Oncol. 2006;32:1222–5.

    Article  CAS  Google Scholar 

  8. Stuart OA, Stephens AD, Welch L, Sugarbaker PH. Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol. 2002;9:186–91.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Muenchen Klinik Bogenhausen, Munich, Germany

    Gabriel Glockzin

Authors
  1. Gabriel Glockzin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriel Glockzin .

Editor information

Editors and Affiliations

  1. Department of Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität of Berlin, Berlin, Germany

    Beate Rau

  2. Department of General, Visceral and Transplant Surgery, University Hospital of Tübingen, Comprehensive Cancer Center, Tübingen, Germany

    Alfred Königsrainer

  3. Basingstoke and North Hampshire Hospital, Peritoneal Malignancy Institute, Basingstoke, UK

    Faheez Mohamed

  4. Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, DC, USA

    Paul H. Sugarbaker

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Glockzin, G. (2021). Safety Considerations for Intraoperative Use of Cytostatic Agents. In: Rau, B., Königsrainer, A., Mohamed, F., Sugarbaker, P.H. (eds) Peritoneal Tumors and Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-62640-2_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62640-2_32

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62639-6

  • Online ISBN: 978-3-030-62640-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation